1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;

3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole;

3-[3-((4-fluorophenyl)(1H-indazol-3-yl)]-5-[(4-pyrrolidinylpiperidyl)methyl]-1H-1,2,4-triazole;

5-(3-((1E)-2-phenylvinyl)-1H-indazole-5yl)-2H-1,2,3,4-tetrazole;

or a pharmaceutically acceptable salt thereof.

REMARKS

Claims 5, 6, 10-13, 18-20, 22-69, 71-93, 98-110, 114-119 are presently pending, claims 22-69, 75-84, 86 and 87 having been withdrawn from consideration as being drawn to a non-elected group. Claims 5, 6, 10-13, 18-20, 71-74, 85, 107-109, 114 and 115 have been amended to recite particular embodiments of the invention. New claims 118 and 119 have been added, which read on elected Group I. No new matter has been added. Claims 14-17, 94-97 and 111-113 have been canceled without prejudice. Applicants fully reserve their right to prosecute the subject matter of any canceled claim in one or more continuation, continuation-in-part or divisional applications.

Applicants gratefully acknowledge the Examiner's indication that the subject matter of claim 117 is allowed over the art of record.

New claims 118 and 119 are independent claims reciting particular species of elected Group I, but which do not fall within presently claimed subclasses. All compounds recited in independent claims 118 and 119 are found in the specification as filed and read on elected Group I. Support for the amended and new claims can be found in Table 1, below.

Table 1: Support for Amended and New Claims

Claim Number	Support
5	page 8, line 2; claim 5 as filed
6	page 8, line 2; claim 6 as filed
10	page 8, line 5; claim 10 as filed
11	page 8, line 5; claim 11 as filed
12	page 8, line 6; claim 12 as filed
13	page 8, line 7; claim 13 as filed
18	page 9, lines 30-34; claim 18 as filed
19	page 9, line 18; claim 19 as filed
20	page 8, line 12; claim 20 as filed
71	page 8, line 12 and lines 20-22; claim 71 as filed
72	page 8, line 12 and lines 20-22; claim 72 as filed
73	page 8, line 12 and lines 20-22; claim 73 as filed
74	page 8, line 12 and lines 20-22; claim 74 as filed
85	page 8, line 12; claim 85 as filed
107	page 81, Example 73 has been removed
108	page 106, Example 110 has been added page 85, Example 78; and page 133, Example 148 have been removed
109	page 74, Example 60; page 77, Example 67; and page 106, Example 110 have been removed
114	page 112, Example 118; pages 339-345, Examples 366-370 ; page 352, Example 375 have been added page 166, Example 184; pages 177-178, Examples 197 and 198; page 181, Example 201; page 225, Example 248; page 232, Example 254; page 283, Example 298; page 288, Example 303; page 290, Example 306; pages 295-297, Examples 312 and 313; pages 306-308, Examples 324-326; page 313, Example 331; page 365, Example 390 have been removed

115	page 147, Example 162; page 164, Example 181; page 272, Example 286 have been removed
118	page 39, Examples 7 and 8; page 74, Example 60; page 77, Example 67; page 85, Example 78; page 225, Example 248; page 232, Example 254; page 283, Example 298; page 288, Example 303; page 290, Example 306; pages 295-297, Examples 312 and 313; page 365, Example 390; page 272, Example 286
119	page 80, Example 72; page 83, Example 75; pages 113-115, Examples 120-123; pages 116-117, Examples 125-126; pages 118-120, Examples 128-131; pages 128-129, Examples 141-142; pages 190-191, Examples 212-214; pages 204-205, Examples 227-228; page 209, Example 233; page 210, Example 235; page 336, Example 363; pages 120-127, Examples 132-140; page 130-132, Examples 143-147; pages 56-58, Examples 33-37; page 198, Example 221; page 261, Example 274; pages 269-270, Examples 283-284; page 304, Example 322; pages 306-307, Examples 324-326; page 337, Example 364; page 387, Example 421; page 166, Example 184; pages 177-178, Examples 197 and 198; page 181, Example 201; pages 306-308, Examples 324-326; page 313, Example 331; page 147, Example 162;

I. The Rejection of claims 5, 6, 10-20, 71-74, 85 and 88-116 Under 35 U.S.C. §112, Second paragaph

Claims 5, 6, 10-20, 71-74, 85 and 88-116 have been rejected under 35 U.S.C. § 112, second paragraph, as being allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as their invention. In particular, it is alleged that the variable "a" and its definition are not needed in claims 5 and 6; the variable R_4 and its definition are not needed in claims 10-13 and 71-74; and the variable "d" and its definition are not needed in claims 10-20, 71-74 and 85.

Claims 5 and 6 have been amended to no longer recite the variable "a" and its definition. Claims 10-13 and 71-74 have been amended to no longer recite the variable R_4 and its definition. Claims 10-13, 18-20 71-74 and 85 have been amended to no longer recite the variable "d" and its definition. Claims 14-17 and 94-97 have been canceled herein without prejudice.

Claims 88-105 are directed to compositions comprising a compound of claim 5, 6, 10-20, 71-74 or 85; and a pharmaceutically acceptable carrier. In view of the amendments to claims 5, 6, 10-13, 18-20, 71-74 and 85 and the cancellation of claims 14-17 and 94-97, Applicants believe the rejection of claims 88-93 and 98-105 (claims 94-97 having been canceled without prejudice) under 35 U.S.C. § 112, second paragraph, has been overcome.

With respect to claims 106-116, it is alleged that each of the claims has a minimum of one compound listed that does not have antecedent basis. In response, Applicants have deleted the recitation of compounds determined not to be embraced by the claim from which they depend, including those compounds cited by the Examiner, and have added new claims 118 and 119 which encompass compounds not embraced by a particular subclass. Claims 111-113 have been canceled herein without prejudice. The compounds of claims 111-113 are now included in new claims 118 and 119.

Thus, in view of these amendments and cancellations, it is believed that the rejection of claims 5, 6, 10-20, 71-74, 85 and 88-116 under 35 U.S.C. § 112, second paragraph, has been overcome and should be withdrawn.

II. The Rejection of claim 13 Under 35 U.S.C. §102(a)

Claim 13 has been rejected under 35 U.S.C. § 102(a) as allegedly being anticipated by United Kingdom Patent Publication No. GB 2,345,486 by Carter *et al.* ("Carter").

Claim 13 has been amended to delete the recitation that R_3 encompasses "substituted heterocycle." The named compound of Carter at page 139, lines 10-11 possesses a substituted furan moiety at the position that corresponds to R_3 of claim 13. Thus, amended claim 13 does not embrace any compound of Carter.

Thus, in view of this amendment, it is believed that the rejection of claim 13 under 35 U.S.C. § 102(a) has been overcome and should be withdrawn.

III. The Rejection of claims 10 and 14 Under 35 U.S.C. §102(b)

Claims 10 and 14 have been rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Chemical Abstracts No. 122:314528 (1995) ("Andronati Abstract"); Chemical Abstracts No. 120:299030 (1994) ("Buck Abstract"); Chemical Abstracts No. 112:216936 (1990) ("Grayshan Abstract"); Chemical Abstracts No. 107:198159 (1987) ("Fujimura II Abstract"); Chemical Abstracts No. 100:51503 (1984) ("Jones Abstract"); Chemical Abstracts No. 97:72295 (1982) ("Pfoertner Abstract"); Chemical Abstracts No.

84:31053 (1976) ("Fujimura I Abstract"); Chemical Abstracts No. 83:164108 (1979) ("Walser Abstract"); and Chemical Abstracts No. 70:77962 (1969) ("Horner Abstract").

Applicants respectfully disagree that the compounds of the Andronati Abstract or its corresponding full paper, S.A. Andronati, *Dopov. Akad. Nauk. Ukr.* 8:126-131 (1994) (the "Andronati Publication"), anticipate claim 10. The compounds of the Andronati Abstract and the Andronati Publication require a halogen or methyl group at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of the Andronati Abstract and the Andronati Publication do not anticipate claim 10.

Applicants respectfully disagree that the compounds of the Buck Abstract or its corresponding full paper, K.T. Buck, *Heterocycles* 36(11):2489-2495 (1993) (the "Buck Publication"), anticipate claim 10. The compounds of the Buck Abstract and the Buck Publication require a hydroxyl group at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of the Buck Abstract and the Buck Publication do not anticipate claim 10.

Applicants respectfully disagree that the compounds of the Grayshan Abstract or its corresponding publication, International Publication No. WO 89/10924 by Grayshan *et al.* (the "Grayshan Publication"), anticipate claim 10. The compounds of the Grayshan Abstract and the Grayshan Publication require a halogen at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of the Grayshan Abstract and the Grayshan Publication do not anticipate claim 10.

Claim 10 has been amended to delete the recitation that R_5, R_6 and R_7 can be hydrogen. The compounds of the Fujimara II Abstract and its corresponding full paper, Y. Fujimura *et al.*, *Yakugaku Zasshi* 106(11):1002-1007 (1986) (the "Fujimura II Publication"), require an aldehydo, methyl, halo or cyano group at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$, wherein R_5 is not hydrogen. Accordingly, the compounds of the Fujimara II Abstract and the Fulimura II Publication do not anticipate claim 10.

Applicants respectfully disagree that the compounds of the Jones Abstract or its corresponding full paper, W.D. Jones, Jr., *et al.*, *J. Heterocyclic Chem.* 20:1359 (1983) (the "Jones Publication"), anticipate claim 10. The compounds of the Jones Abstract and the

Jones Publication require a halogen group at the position which corresponds to the variable R_2 of claim 10, wherein in contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of the Jones Abstract and the Jones Publication do not anticipate claim 10.

Applicants respectfully disagree that the compounds of the Pfoertner Abstract or its corresponding full paper, K-H. Pfoertner *et al.*, *Helv. Chim. Acta* 65(3):798-806 (1982) (the "Pfoertner Publication"), anticipate claim 10. The compounds of the Pfoertner Abstract and the Pfoertner Publication require a halogen group at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of Pfoertner Abstract and the Pfoertner Publication do not anticipate claim 10.

Applicants respectfully disagree that the compounds of the Fujimura I Abstract or its corresponding publication, United Kingdom Patent Publication No. GB 1,489,280 by Fujimura *et al.* (the "Fujimura I Publication"), anticipate claim 10. The compounds of the Fujimura I Abstract and the Fujimura I Publication require a halogen or methyl group at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of the Fujimura I Abstract and the Fujimura I Publication do not anticipate claim 10.

Applicants respectfully disagree that the compounds of the Walser Abstract or its corresponding full paper, A. Walser et al., *J. Heterocycl. Chem.* 11:885-888 (1974) (the "Walser Publication"), anticipate claim 10. The compounds of the Walser Abstract and the Walser Publication require a halogen group at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of theWalser Abstract and the Walser Publication do not anticipate claim 10.

Applicants respectfully disagree that the compounds of the Horner Abstract or its corresponding publication, German Patent Publication No. 1,266,763 by Horner *et al.* (the "Horner Publication"), anticipate claim 10. The compounds of the Horner Abstract and the Horner Publication require a halogen or alkoxy group at the position which corresponds to the variable R_2 of claim 10. In contrast, the variable R_2 of claim 10 is defined as $-(CH_2)_bC(=O)R_5$. Accordingly, the compounds of the Horner Abstract and the Horner Publication do not anticipate claim 10.

Claim 14 has been canceled without prejudice herein.

Thus, in view of the above arguments, amendment and cancellation, it is believed that the rejection of claim 10 (claim 14 having been canceled without prejudice) under 35 U.S.C. § 102(b) has been overcome and should be withdrawn.

IV. The Rejection Under 35 U.S.C. §102(e)

Claims 5, 13-17, 88 and 93-97 have been rejected under 35 U.S.C. § 102(e) as allegedly being anticipated by U.S. Publication No. 2002/0161022 by Reich *et al.* ("Reich").

Reich discloses indazole compounds wherein R_2 can be a substituted or unsubstituted alkyl, aryl, heteroaryl, carbocycle, heterocycle group or:



wherein R_4 is H or lower alkyl, and X is a substituted or unsubstituted aryl, heteroaryl, carbocycle, or heterocycle group.

Claim 5 has been amended to delete the recitation that R_2 is R_4 and that R_3 is alkyl, haloalkyl, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl or heterocycle fused to phenyl. None of the functionality represented by R_2 or R_3 in amended claim 5 is encompassed by the definition of R_2 as set forth in Reich.

Amended claim 13 relates to compounds wherein R_2 is $-(CH_2)_bNR_5R_6$. As discussed above, the compounds of Reich are those wherein R_2 can be substituted or unsubstituted alkyl, aryl, heteroaryl, carbocycle, heterocycle group or the group illustrated above. Nowhere in Reich are compounds disclosed wherein R_2 is $-(CH_2)_bNR_5R_6$.

Claims 88 and 93 relate to compositions comprising the compound of claim 5 and claim 13, respectively, and a pharmaceutically acceptable carrier. Because amended claim 5 and amended claim 13 do not encompass any compounds disclosed in Reich, Applicants believe that the rejection of claims 88 and 93 under 35 U.S.C. § 102(e) has been overcome

Claims 14-17 and 94-97 have been canceled without prejudice.

Thus, in view of the above arguments, amendments and cancellations, it is believed that the rejection of claims 5, 13, 88 and 93 (Claims 14-17 and 94-97 having been canceled) under 35 U.S.C. § 102(e) has been overcome and should be withdrawn.

V. The Rejection Under 35 U.S.C. §103(a)

Claims 5, 13-20, 71-74, 85, 88, 94-105 and 111-116 have been rejected under 35 U.S.C. § 103(a) as being allegedly obvious over Reich.

As discussed above, claim 5 has been amended to delete the recitation that R_2 is R_4 and that R_3 is alkyl, haloalkyl, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl or heterocycle fused to phenyl. None of the functionality represented by R_2 or R_3 in amended claim 5 is encompassed, disclosed or suggested by this definition of R_2 as set forth in Reich.

Also discussed above, amended claim 13 relates to compounds wherein R_2 is $-(CH_2)_bNR_5R_6$. In contrast, the compounds of Reich are those wherein R_2 can be substituted or unsubstituted alkyl, aryl, heteroaryl, carbocycle, heterocycle group or the group illustrated above. Nowhere in Reich are compounds disclosed or suggested wherein R_2 is $-(CH_2)_bNR_5R_6$.

Amended claims 18 and 85 relate to compounds wherein R_2 is 3-triazolyl. Reich does not disclose or suggest compounds wherein R_2 is 3-triazolyl.

Amended claim 19 relates to compounds wherein R_2 is tetrazole. Reich does not disclose or suggest compounds wherein R_2 is tetrazole.

Amended claim 20 relates to compounds wherein R_2 is imidazole. Reich does not disclose or suggest compounds wherein R_2 is imidazole.

Amended claims 71 and 73 relate to compounds wherein R_2 is-$(CH_2)_bC(=O)NR_5R_6$, $(CH_2)_bNR_5C(=O)R_6$, 3-triazolyl or 5-tetrazolyl. Reich does not disclose or suggest compounds wherein R_2 is $-(CH_2)_bC(=O)NR_5R_6$, $(CH_2)_bNR_5C(=O)R_6$, 3-triazolyl or 5-tetrazolyl.

Amended claims 72 and 74 relate to compounds wherein R_2 is 3-triazolyl or 5-tetrazolyl. Reich does not disclose or suggest compounds wherein R_2 is 3-triazolyl or 5-tetrazolyl.

As discussed above, the compounds of Reich are those wherein R_2 can be substituted or unsubstituted alkyl, aryl, heteroaryl, carbocycle, heterocycle group or the

group illustrated above. None of the compounds of amended claims 5, 13, 18-20, 71-75, 85, 88, 98-105 or 114-116 are disclosed or suggested by Reich.

Accordingly, none of the presently claimed compounds is embraced or suggested by Reich.

The Federal Circuit has expressly required that "there must be adequate support in the prior art for the ... change in structure, in order to complete the PTO's *prima facie* case [of obviousness] and shift the burden of going forward to the applicant." *In re Grabiak*, 769 F.2d 729, 732, 226 USPQ 870, 872 (Fed. Cir. 1985).

The Federal Circuit, explaining that the PTO cited no reference showing or suggesting to one of ordinary skill in the art the interchangeability of a sulfur atom for an oxygen atom in the type of compound claimed by *Grabiak*, held:

> The Bollinger teaching of various heterocyclic rings containing either two sulfur atoms or one oxygen and one sulfur atom, rings which are unlike any part of the Howe molecule, does not suggest the interchangeability of sulfur for oxygen in the ester moiety of the Howe molecule. . . . Conant & Blatt's brief discussion that "simple sulfur compounds" have properties similar to simple oxygen compounds does not purport to apply to complex organic molecules. . . . In the absence of such reference, there is inadequate support for the PTO's position that this modification would prima facie have been obvious.

Grabiak, 769 F.2d at 732.

Thus, in view of *Grabiak*, for a compound that differs from the prior art by at least one atom to be obvious, the Examiner must provide a secondary reference that teaches the interchangeability of such at least one atom of the claimed compound with the corresponding atom of the prior art.

Absent any secondary reference suggesting the interchangeability of the functional groups of the presently claimed compounds with those disclosed in Reich, an allegation of obviousness is unsupported and cannot stand. Therefore, the rejection of claims 5, 13, 18-20, 71-74 and 85 (claims 14-17, 94-97 and 111-113 having been canceled without prejudice) under 35 U.S.C. § 103(a) over Reich cannot stand and must be withdrawn.

Claims 88 and 98-105 relate to pharmaceutical compositions comprising a compound of the claim from which each depends (*i.e.*, claims 5, 18-20, 71-74 and 85, respectively) and a pharmaceutically acceptable carrier. In view of the amendments and remarks above with respect to the claims from which these claims depend, Applicants

believe that the rejection of claims 88 and 98-105 under 35 U.S.C. § 103(a) has been overcome.

Thus, in view of the above, it is believed that the rejection of claims 5, 13, 18-20, 71-74, 85, 88, 98-105 and 114-116 (claims 14-17, 94-97 and 111-113 having been canceled without prejudice) under 35 U.S.C. § 103(a) has been overcome and must be withdrawn.

Conclusion

Applicants respectfully request that the present amendments be entered and the present remarks be made of record in the file history of the present application. An early allowance of the application is earnestly requested. The Examiner is invited to call the undersigned with any questions concerning the foregoing.

Applicants believe that the only fees due are those for the amendments, extension of time (1 month) and filing of the information disclosure statement; however, in the event any additional fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: May 27, 2003 By: Anthony M. Insogna, Ly. No. 35,203 / Matthew E. Lee, Ly. No. 36,343

Anthony M. Insogna (Reg. No. 35,203)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

EXHIBIT A

U.S. PATENT APPLICATION SERIAL NO. 09/910,950
MARKED-UP VERSION OF ALL AMENDED CLAIMS

5. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is $-(CH_2)_bCH=CH(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is $-R_3$, **[-R_4,]** $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$, $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

[*a* is 1, 2, 3, 4, 5 or 6;]

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, **[alkyl,]** alkoxy, **[haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,]** $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$**[, or heterocycle fused to phenyl]**;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

6. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$, $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

[*a* is 1, 2, 3, 4, 5 or 6;]

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR_8, -C(=O)R_8, -C(O)NR_8R_9, -C(=O)NR_8OR_9, -$SO_2NR_8R_9$, -$NR_8SO_2R_9$, -CN, -NO_2, -NR_8R_9, -NR_8C(=O)R_9, -NR_8C(=O)$(CH_2)_bOR_9$, -NR_8C(=O)$(CH_2)_bR_9$, -$O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

10. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, -$(CH_2)_a$-, -$(CH_2)_b$CH=CH$(CH_2)_c$-, or -$(CH_2)_b$C≡C$(CH_2)_c$-;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is -$(CH_2)_b$C(=O)R_5;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]

R_5, R_6 and R_7 are the same or different and at each occurrence independently **[hydrogen,]** alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

11. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is $-(CH_2)_bC(=O)NR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted **with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]**

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

12. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is $-(CH_2)_bNR_5C(=O)R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9

taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

13. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is $-(CH_2)_bNR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, **[substituted heterocycle,]** heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

18. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is R_4;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is 3-triazolyl, optionally substituted at its 5-position with:

(a) a C_1-C_4 straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or

(b) a 2-pyrrolidinyl group;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

19. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is R_4;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl,

heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is tetrazole;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

20. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is R_4;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is imidazole;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

71. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bNR_5C(=O)R_6$, 3-triazolyl or 5-tetrazolyl;

a is 1, 2, 3, 4, 5 or 6;

b is 0;

c is at each occurrence 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one **to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]**

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

72. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is 3-triazolyl or 5-tetrazolyl;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

73. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

-A-R_1 is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -$NR_8C(=O)R_9$, -$C(=O)NR_8R_9$,

and -$O(CH_2)_bNR_8R_9$, wherein *b* is 2 or 3;

R_2 is -$(CH_2)_bC(=O)NR_5R_6$, -$(CH_2)_bNR_5C(=O)R_6$, 3-triazolyl or 5-tetrazolyl, wherein *b* is 0;

a is 1, 2, 3, 4, 5 or 6;

c is at each occurrence 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -$C(=O)OR_8$, -$C(=O)R_8$, -$C(O)NR_8R_9$, -$C(=O)NR_8OR_9$, -$SO_2NR_8R_9$, -$NR_8SO_2R_9$, -CN, -NO_2, -NR_8R_9, -$NR_8C(=O)R_9$, -$NR_8C(=O)(CH_2)_bOR_9$, -$NR_8C(=O)(CH_2)_bR_9$, -$O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9

taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

74. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

-A-R_1 is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -$NR_8C(=O)R_9$, -$C(=O)NR_8R_9$, and -$O(CH_2)_bNR_8R_9$;

R_2 is 3-triazolyl or 5-tetrazolyl;

a is 1, 2, 3, 4, 5 or 6;

b is 2 or 3;

c is at each occurrence 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -$C(=O)OR_8$, -$C(=O)R_8$, -$C(O)NR_8R_9$, -$C(=O)NR_8OR_9$, -$SO_2NR_8R_9$, -$NR_8SO_2R_9$, -CN, -NO_2, -NR_8R_9, -$NR_8C(=O)R_9$, -$NR_8C(=O)(CH_2)_bOR_9$, -$NR_8C(=O)(CH_2)_bR_9$, -$O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

[R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R_3, or R_4 is halogen or hydroxy;]

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

85. (Twice amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R_3;

R_2 is R_4;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

[*d* is at each occurrence 0, 1 or 2;]

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is 3-triazolyl, optionally substituted at its 5-position with:

(a) methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-pyrrolidinylmethyl or 2-pyrrolidinyl;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independently selected from R_3; and

R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R_3.

107. (Amended) A compound of claim 10, wherein the compound is:

[3-(4-fluorophenyl)-1H-indazole-5-carboxylic acid;]

1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl} piperidine-4-carboxylic acid;

3-(4-fluorophenyl)(1H-indazol-5-yl) pyrrolidinyl ketone;

3-(4-fluorophenyl)(1H-indazol-5-yl)piperazinyl ketone;

1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-one;

1-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethan-1-one; or a pharmaceutically acceptable salt thereof.

108. (Amended) A compound of claim 11, wherein the compound is:

3-(4-fluorophenyl)-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-benzamide;

N-(2-(dimethylamino)ethyl)3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;

[ethyl 1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl}piperidine-4-carboxylate;]

methyl 4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}benzoate;

4-{3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}benzoic acid;

4-{(3-(4-fluorophenyl)-1H-indazole-5-yl)carbonylamino}benzamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-pyridyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridyl)carboxamide;

tert-butyl 3-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)propanoate;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxyphenyl)carboxamide;

3-{(3-(4-fluorophenyl)-1H-Indazol-5-yl)carbonylamino)propanoic acid;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-nitrophenyl)carboxamide;

tert-butyl-2-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}acetate;

4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino} butanoic acid;

N-(3-aminophenyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

2-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}acetic acid;

5-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}pentanoic acid;

4-({(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}methyl)benzoic acid;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridylmethyl)carboxamide;

2-(4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}phenyl)acetic acid;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N,N-dimethylcarboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarboxamide;

N-(3-aminoethyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

N-(3-aminopropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxypropyl)carboxamide;

N-(2H-1,2,3,4-tetrazol-5-yl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

{3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-morpholin-4-ylpropyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-pyridylmethyl)carboxamide;

N-(((2R)-2-hydroxycyclohexyl)methyl)(3-(4-fluorophenyl)(1H-indazole-5-yl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-(1-methylimidazol-5-yl)ethyl)carboxamide);

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridylmethyl)carboxamide;

N-(2-carbamoylethyl)(3 -(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

N-(3-carbamoylpropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

[1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-one;]

3-(4-methoxyphenyl)-1H-indazole-5-carboxamide;

3-(4-hydroxyphenyl)-1H-indazole-5-carboxamide;

3-(2-naphthyl)-1H-indazole-5-carboxamide;

3-benzo(b)thiophen-2-yl-1H-indazole-5-carboxamide;

3-benzo(d)furan-2-yl-1H-indazole-5-carboxamide;

3-(3-(methylethyl)phenyl)-1H-indazole-5-carboxamide;

3-(4-(dimethylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-furyl)-1H-indazole-5-carboxamide;

3-{4-(2-(dimethylamino)ethoxy)phenyl}-1H-indazole-5-carboxamide;

3-(3,4-dimethoxyphenyl)-1H-indazole-5-carboxamide;

3-(3-aminophenyl)-1H-indazole-5-carboxamide;

3-(2H-benzo(d)1,3-dioxolen-5-yl)-1H-indazole-5-carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(methylethyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-(dimethylamino)ethyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(4-(dimethylamino)butyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(3-(dimethylamino)propyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methylpropyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-methylcarboxamide;

3-(3-(3-pyridylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-methoxyacetylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(4-piperidylcarboxyamino)phenyl)-1H-indazole-5-carboxamide;

(1S)-1-{N-(3-(5-carbamoyl(1H-indazol-3-yl))phenyl)carbamoyl}ethyl acetate;

3-{3-(2-methoxyethyl)amino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(3-piperidylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-furylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-{3-(2-(dimethylamino)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(2-phenylacetylamino)phenyl)-1H-Indazole-5-carboxamide;

3-{3-(2-(4-methoxyphenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(2-methyl-1,3-thiazol-5-yl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(oxolan-3yl-carbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-(3-thienyl)acetylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-thienylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-(4-pyridyl)acetylamino)phenyl)-1H-Indazole-5-carboxamide;

3-(3-(2-(2-pyridyl)acetylamino)phenyl)-1H-Indazole-5-carboxamide;

3-{3-(2-(4-fluorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(cyclopropylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-{3-((3-hydroxyphenyl)carbonylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(2,4-dichlorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-{2-(4-(trifluoromethyl)phenyl)acetylamino}phenyl)-1H-indazole-5-carboxamide;

3-(3-{2-(4-(dimethylamino)phenyl)acetylamino}phenyl)-1H-indazole-5-carboxamide;

3-{3-(2-(2-chloro-4-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(4-chlorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(3-phenylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;

3-{3-(3-(4-fluorophenyl)propanoylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(3,4-difluorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(2-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(2-phenylpropanoylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(2-piperidylethoxy)phenyl}-1H-indazole-5-carboxamide;

N-ethyl-3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino} propanamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-methoxypropyl)carboxamide;

3-{3-(N-(2-piperidylethyl)carbamoyl)phenyl}-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxyethyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxypropyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(oxolan-2-ylmethyl)carboxamide;

3-(2H, 3H-benzo(e)1,4-dioxin-6-yl)-1H-indazole-5-carboxamide;

3-(3-quinolyl)-1H-indazole-5-carboxamide;

3-(6-methoxy-2-naphthyl)-1H-indazole-5-carboxamide;

3-(2,3-dihydrobenzo(b)furan-5-yl)-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-oxo-3-pyrrolidinylpropyl) carboxamide;

3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-methyl propanamide;

3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N,N-dimethyl propanamide;

3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-(2-methoxyethyl)propanamide; or a pharmaceutically acceptable salt thereof.

109. (Amended) A compound of claim 12, wherein the compound is:

phenyl-N-(3-phenyl(1H-indazol-5-yl))carboxamide;

N-(3-phenyl(1H-indazol-5-yl))-2-pyridylcarboxamide;

methyl 4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoate;

4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoic acid;

(2-hydroxyphenyl)-N-(3-phenyl(1H-indazol-5-yl)carboxamide;

N-(3-(phenyl-1H-indazole-5-yl))acetamide;

[(4-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carlboxamide;]

(4-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;

(3-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl)) (2-methylphenyl)carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-methoxyphenyl)carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4-phenylphenyl)carboxamide;

benzo(b)thiophen-2-yl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

methyl 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoate;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-pyridylcarboxamide;

4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;

cyclopropyl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

methyl 4-{N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoate;

4-{N-(3-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoic acid;

methyl 3-{N-((4-fluorophenyl)-1H-indazol-5-yl}carbamoyl}benzoate;

3-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;

N-(3-(4-fluorophenyl)-(1H-indazol-5-yl))(4-(N-methylcarbamoyl)phenyl)carboxamide;

4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzamide;

1-4-{N-(3-(4-methoxyphenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;

4-(N-(3-(4-pyridyl)-1H-indazol-5-yl)carbamoyl)benzoic acid;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl)benzamide;

(3,4-bis(trifluoromethyl)phenyl)-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-furylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(3,4-dichlorophenyl)carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-hydroxyphenyl)carboxamide;

[2-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}phenyl)methyl benzoate;]

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4-pyridylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-pyridylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-thienylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))morpholin-4-yl-carboxamide;

[N-(3-(4-fluorophenyl)(1H-indazol-5-yl))((4-fluorophenyl)amino)carboxamide;]

[N-(((2R)-2-hydroxycyclohexyl)methyl) (3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;] or a pharmaceutically acceptable salt thereof.

114. (Amended) A compound of claim 18, wherein the compound is:

3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-methyl-4H-1,2,4-triazole;

5-{3-(4-fluorophenyl)(1H-indazole-5-yl)]-3-(methylethyl)-4H-1,2,4-triazole;

1-{5-(3-(4-fluorophenyl)-1H-indazole-5-yl)-4H-1,2,4-triazol-3-yl} propan-2-ol;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-propyl-4H-1,2,4-triazole;

5-{3-(3-(methylethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenol;

(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)dimethylamine;

[3-(3-((1E)-2-phenylvinyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;]

{2-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}dimethylamine;

3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)furan;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;

5-(3-naphthyl-1H-indazol-5-yl)-1H-1,2,4-triazole;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)thiophene;

5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenylamine;

3-(3-(3,4-dichlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;

3-(3-(4-methylphenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)acetamide;

5-(3-(3-chlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

[1-((1E)-2-(5-(1H-1,2,4-triazol-3-yl)((1H-indazol-3-yl))vinyl)-4-methoxybenzene;]

[3-{3-((1E)-2-(4-chlorophenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;]

2-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfonyl)benzene;

[3-{3-((1E)-2-(4-methylphenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;]

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfinyl)benzene;

5-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;

4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenylamine;

5-{3-(4-(trifluoromethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)) phenyl) (methylsulfonyl)amine;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;

5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;

1-{5-{3-(4-fluorophenyl)1H-indazol-5-yl}-4H-1,2,4-Triazol-3-yl}ethan-1-ol;

1-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl}-4H-1,2,4-triazol-3-yl}propan-2-ol;

{3-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl}dimethylamine;

{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-yl-ethoxy)benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-pyrrolidinylethoxy) benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;

1-{2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethyl} pyrrolidin-2-one;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperazinylethoxy) benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(3-piperdylpropoxy) benzene;

4-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}-1-acetylpiperazine;

[N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} (phenylmethoxy) carboxamide;]

2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethylamine;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-cyclohexylethoxy) benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-azaperhyroepinylethoxy)benzene;

N-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furyl caroxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-benzyl caroxamide;

[N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl)phenoxy)ethyl}acetamide;]

5-(3-(2-chlorophenyl)-1H-indazol-3-yl)-1H-1,2,4-triazole;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2,2-dimehtylpropyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(cyclopropylmethyl)carboxamide;

(3-(5-(1H-1,2,4-trizol-5-yl)(1H-indazol-3-yl))phenyl)-N-(3-pyridylmethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-4-methyl piperazinyl ketone;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl) carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-indan-2-ylcarboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)indanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S)indanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S,2R)-2-hydroxyindanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((2S,1R)-2-hydroxyindanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1-methyl-1-phenylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(tert-butyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)-1-phenylethyl)carboxamide;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl-isoindolin-2-yl ketone;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2-(dimethylamino) ethyl)carboxamide;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1R)indanyl benzene;

{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-(1,2,4)-triazol-3-ylmethyl}-dimethyl-amine;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxypropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(dimethylamino)acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)butanamide;

[2E-N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-phenylprop-2-enamide;]

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenoxypropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopropylcarboxamide;

[N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-indol-3-yl-2-oxoacetamide;]

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(6-chloro(3-pyridyl))carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopentylcarboxamide;

[N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)methane carboxylic acid;]

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzo(b)thiophen-2-carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-furylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)isoxazol-5-ylcarboxamide;

[N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(2-furyl)-2-oxoacetamide;]

[N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-oxo-2-phenylacetamide;]

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)pentanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-4-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-cyclohexylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-propanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-fluorophenyl)acetic acid;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2R)-2-hydroxy-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxy-2-phenylacetamide;

(2-{3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;

diethyl({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)amine;

[4-({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-1H-1,2,4-triazol-5-yl}methyl)morpholine;]

[4-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl}methyl)morpholine;]

[1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;]

({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)methylamine;

({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;

(2R)-N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;

N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;

[3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole;]

N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-methylbutanamide;

N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;

(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)carboxamide;

(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3yl)}(1H-indazol-3-yl))phenyl)-N-((*tert*-butyl)methyl)carboxamide;

((1R)indanyl)(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)carboxamide;

({3-(3-(4-methoxyphenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)dimethylamine;

{(3-(3-(2H-benzo(d)1,3-dioxolen-5-yl))(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl}dimethylamine;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-(2-piperidylethyl)carboxamide;

((5-(3-benzo(D)furan-2-yl(1H-indazol-5-yl))(1H-1,2,4-triazol-3-yl))methyl)dimethylamine;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-benzamide;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-(4-fluorophenyl)carboxamide-2HCl;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-indan-2-yl-carboxamide;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-cyclopropylcarboxamide;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-cyclobutylcarboxamide-2HCl;

1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(2-methoxyethoxy)benzene;

1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(3-pyridylmethoxy)benzene;

3-(5-(1H-1,2,4-triazol-3-y)-1H-indazol-3-yl)benzoic acid;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)benzoic acid N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(3-pyridyl)acetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(dimethylamino)acetamide;

(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(methylsulfonyl)amine;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-methoxyethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-benzamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-phenethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(2-piperidylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(2-morpholin-4-ylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclohexylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclopentylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(4-fluorophenyl)carboxamide;

[(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-{2-(1-benzyl(4-piperidyl))ethylcarboxamide;]

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-((1R,2R)-2-phenylcyclopropyl) carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclopropylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(3-pyridyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(5,6,7,8-tetrahydronaphthyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(1-benzyl(4-piperidyl))carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(1-benzylpyrrolidin-3-yl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(methylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclobutylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(4-pyridyl)carboxamide;

6-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2H,3h-benzo(e)1,4-dioxin;

6-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))-2-methoxynaphthalene;

3-(3-(3-quinoyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

5-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2,3-dihydrobenzo(b)furan;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2,4-dichlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methoxyphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methylphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-chlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-methylbutanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-morpholin-4-yl-acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-methylpiperazinyl)acetamide;

[3-(3-(4-fluorophenyl)(1H-indazol-3-yl))-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole;]

[({3-(3-(6-methoxy(2-naphthyl))(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)dimethylamine;]

2-methoxy-6-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}naphthalene;

N-phenyl(3-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}phenyl)carboxamide;

6-{5-(5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl}-2H,3H-benzo(e)1,4-dioxin; or a pharmaceutically acceptable salt thereof.

115. (Amended) A compound of claim 19, wherein the compound is:

5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-2-methoxybenzene;

[5-(3-((1E)-2-phenylvinyl)-1H-indazole-5yl)-2H-1,2,3,4-tetrazole;]

5-(3-(3-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;

5-{3-(4-(methylethyl)phenyl)-1H-indazol-5-yl}-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)furan;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenylamine;

5-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;

5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-methylpropoxy)benzene;

5-(3-(4-chlorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-3-methoxybenzene;

5-(3-(4-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;

5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;

5-(3-(2-phenylethyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

[5-{3-(3-(methylethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;]

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

2-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-morpholin-4-ylethoxy)benzene;

N-(3-(5-2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)2-phenoxypropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-ylethoxy)benzene;

4-(5-(2H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-1,2-dimethoxybenzene;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-methoxypropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;

{3-(4-(5-(1H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenoxy)propyl}dimethylamine;

{3-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl}dimethylamine;

{2-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}dimethylamine;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxypropanamide;

[(1S)-1-{N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl) carbamoyl}ethyl acetate;]

N-(4-(5-(2H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide; or a pharmaceutically acceptable salt thereof.